Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Nobuaki Sato

Koichi Ito

Noritaka Kitazawa

Takashi Doko

Toshihiko Kaneko

Koki Kawano

Teiji Kimura

Mamoru Takaishi

Hiroaki Hagiwara

Takehiko Miyagawa

Takeo Sasaki

Taro Terauchi

Eriko Doi

Norihito Ohi

Motohiro Soejima

Atsushi Kamada

Manabu Sasho

Naohiro Kohmura

Takaaki Suzuki

Isao Sugiyama

Hitoshi Oinuma

Yoshihiko Norimine

Yu Yoshida

Yoshimitsu Naoe

Daisuke Shinmyo

Daiju Hasegawa

Hidenori Seshimo

Toshiyuki Uemura

Tetsuya Kawahara

Mitsuaki Miyamoto

Fumihiro Ozaki

Richard S Clark

Kazuo Okano

Akiharu Kajiwara

Ieharu Hishinuma

Masanobu Shinoda

Hiroshi Tanaka

Fumiyoshi Matsuura

Itaru Tsukada

Makoto Kotake

Kazuhide Ashizawa

Kunitoshi Takeda

Toshiyuki Matsuoka

Ikuo Kushida

Yoshiaki Ohashi

Shuichi Suzuki

Akifumi Kimura

Osamu Ito

Motoji Kogushi

Hiroko Kobayashi

Koji Hagiwara

Tamaki Hoshikawa

Yuki Ishihara

Ken-ichi Chiba

Naoto Ono

Syuhei Miyazawa

Yoshiaki Oohashi

Takeshi Suzuki

Toru Watanabe

Yuichi Suzuki

Shigeto Negi

Tsutomu Kawata

Kanemasa Katsu

Shinsuke Hirota

Takafumi Motoki

Hiroyuki Chiba

Taiju Nakamura

Kenshi Yoshida

Atsushi Kamata

Akio Kayano

Takashi Musha

Nobuhiro Sato

Yoshihisa Kobayashi

Shin Sakurai

Hiroyuki Ishizuka

Hiroyuki Saito

Yuuki Komatsu

Tsutomu Kawada

Takaaki Harada

Hikaru Yoshimura

Takashi Musya

Ken-Ichi Chiba

Keni-Ichi Chiba

Takashii Musha

Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals. 

Salt of pentacyclic compound and crystal thereof

The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof: 

Pentacyclic heterocycles

A compound represented by formula (I), or a pharmaceutically acceptable salt thereof: wherein Rrepresents a group represented by the formula: a group represented by the formula: or a group represented by the formula: and Rrepresents a 3-methyltetrahydro-2H-pyran-4-yl group or 4-methoxycyclohexyl group.

Pyridinylpyrazoloquinoline compounds

Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by A&#x3b2;, wherein Arrepresents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Arrepresents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; Xrepresents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.

Polycyclic compound

A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by A&#x3b2;. 

Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein Ris a hydrogen atom; Ris an aromatic ring group, etc.; Ris a hydrogen atom, etc; Ris a hydrogen atom; Ris an oxepanyl group, etc.; Ris a hydrogen atom.

Pyrazoloquinoline derivatives

The present invention relates to a compound represented by formula (I): wherein Rrepresents a C1-3 alkyl group, Rrepresents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

Bicyclic oxomorpholine derivative

The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A&#x3b2;.

Multi-cyclic cinnamide derivatives

A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Arrepresents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Arrepresents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, Xrepresents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A&#x3b2;.

Imidazoyl pyridine compounds and salts thereof

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.  Wherein Ris a C-Caromatic cyclic hydrocarbon group etc.; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C-Calkylene group etc.; X is a single bond, or a group represented by &#x2014;CO&#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014;, etc.; and Y is a C-Ccycloalkyl group, a C-Caromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

[object Object]

The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Rand Reach denote a C1-6 alkyl group or the like; Xdenotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.

Prodrug of cinnamide compound

The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Arrepresents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Arrepresents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, Xrepresents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A&#x3b2;.

Multi-cycle cinnamide derivatives

The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R, R, R, and Rare the same or different and each represent a hydrogen atom or a C1-6 alkyl group; Xrepresents a C1-6 alkylene group that may be substituted; Xrepresents a methoxy group or a fluorine atom; Xrepresents an oxygen atom or a methylene group, provided that Xis only an oxygen atom when Xis a methoxy group; and Arrepresents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

Morpholine type cinnamide compound

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Ris a C-Caromatic cyclic hydrocarbon group etc.; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C-Calkylene group etc.; X is a single bond, or a group represented by &#x2014;CO&#x2014;NH&#x2014; or &#x2014;NH&#x2014;CO&#x2014;, etc.; and Y is a C-Ccycloalkyl group, a C-Caromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

1H-indazole compounds

Growing community of inventors

Tsukuba, Japan

Nobuaki Sato